Translational Development Acquisition (TDAC) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 29, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TDAC SEC filings page.
This page shows Translational Development Acquisition Corp. (TDAC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The reported balance sheet is an acquisition vehicle, not an operating business: assets are funded by liabilities while cash outflows continue.
FY2025 reported net income of$6.36M contrasted with FY2024's net loss of$71K , a sharp change in accounting results. Yet FY2025 operating cash flow was-$608K , so the latest profit did not translate into cash generated by operations; the supplied ratio was-9.6% .
In FY2025, liabilities of
Current assets fell from
Financial Health Signals
Translational Development Acquisition Corp. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Translational Development Acquisition Corp. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Key Financial Metrics
Earnings & Revenue
Translational Development Acquisition Corp. reported $947K in net income in Q2 2026. This represents a decrease of 41.7% from the same quarter a year earlier. Against the prior quarter it is down 28.9%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Translational Development Acquisition Corp. held $86K in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
TDAC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| SG&A Expenses | $661K+198.9% | $281K-19.1% | N/A | $214K+248.6% | $221K+13023.3% | $347Kn/m | N/A | $61K |
| Operating Income | -$661Kn/m | -$281Kn/m | N/A | -$214Kn/m | -$221Kn/m | -$347Kn/m | N/A | -$61K |
| Income Tax | N/A | $0n/m | N/A | N/A | N/A | $0 | N/A | N/A |
| Net Income | $947K-41.7% | $1.3M-10.1% | N/A | $1.7Mn/m | $1.6Mn/m | $1.5Mn/m | N/A | -$61K |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, EBITDA, Interest Expense, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
TDAC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $157.4M-11.7% | $183.3M+3.8% | $181.7M+3.8% | $180.0M | $178.2M | $176.6M | $175.0M+8659008.3% | N/A |
| Current Assets | $105K-32.9% | $75K-81.9% | $39K-93.9% | $81K | $156K | $415K | $650K+32073.8% | N/A |
| Cash & Equivalents | $86K+143.6% | $25K-88.1% | $30K-93.2% | $47K-79.0% | $35K-51.0% | $207K | $438K+21581.0% | $224K |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0n/m | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0n/m | $0 |
| Total Liabilities | $165.1M-10.5% | $190.2M+4.2% | $188.2M+4.2% | $186.4M | $184.3M | $182.5M | $180.6M+35333.7% | N/A |
| Current Liabilities | $1.8M+515.3% | $861K+166.7% | $544K+158.7% | $423K | $285K | $323K | $210K-58.7% | N/A |
| Non-Current Liabilities | $163.3M-11.3% | $189.3M+3.9% | $187.7M+4.1% | $185.9M | $184.1M | $182.2M | $180.4Mn/m | N/A |
| Total Equity | -$7.7Mn/m | -$6.8Mn/m | -$6.5Mn/m | -$6.4Mn/m | -$6.2Mn/m | -$5.9Mn/m | -$5.6Mn/m | -$571K |
| Retained Earnings | -$7.7Mn/m | -$6.8Mn/m | -$6.5Mn/m | -$6.4M | -$6.2M | -$5.9M | -$5.6Mn/m | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
TDAC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TDAC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$6.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.07), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Translational Development Acquisition Corp. TDAC | FY2025 | N/A | $6.4M | N/A | $209.5M | — |
| Melar Acquisition Corp. I MACI | FY2025 | N/A | $5.5M | N/A | $80.4M | — |
Where Translational Development Acquisition Corp. Ranks
Frequently Asked Questions
Is Translational Development Acquisition Corp. profitable?
Yes, Translational Development Acquisition Corp. (TDAC) reported a net income of $6.4M in fiscal year 2025.
What is Translational Development Acquisition Corp.'s operating cash flow?
Translational Development Acquisition Corp. (TDAC) recorded an outflow of $608K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Translational Development Acquisition Corp.'s total assets?
Translational Development Acquisition Corp. (TDAC) had $181.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Translational Development Acquisition Corp.'s current ratio?
Translational Development Acquisition Corp. (TDAC) had a current ratio of 0.07 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Translational Development Acquisition Corp.'s return on assets (ROA)?
Translational Development Acquisition Corp. (TDAC) had a return on assets of 3.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Translational Development Acquisition Corp.'s P/E ratio?
Translational Development Acquisition Corp. (TDAC) trades at 32.9x earnings, its market capitalization divided by $6.4M net income, FY2025. The market capitalization is $209.5M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Translational Development Acquisition Corp.'s price-to-sales ratio?
Translational Development Acquisition Corp. (TDAC) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $209.5M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is Translational Development Acquisition Corp.'s debt-to-equity ratio negative or not reported?
Translational Development Acquisition Corp. (TDAC) has negative shareholder equity of -$6.5M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Translational Development Acquisition Corp.'s Piotroski F-Score?
Translational Development Acquisition Corp. (TDAC) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.